A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
IsraelCompletedPHASE2
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Conditions
Bladder Cancer · Urothelial Carcinoma · Urothelial Carcinoma Bladder
Locations
- Mayo Clinic Cancer Center, Phoenix, Arizona, United States
- Arkansas Urology, Little Rock, Arkansas, United States
- Loma Linda University, Loma Linda, California, United States
- Providence Medical Institute, Santa Monica, California, United States
- Clinical Research Center of Florida, Pompano Beach, Florida, United States
- John Hopkins University, Baltimore, Maryland, United States
- Adult & Pediatric Urology, PC, Omaha, Nebraska, United States
- Urology Las Vegas, Las Vegas, Nevada, United States
- Manhattan Medical Research, New York, New York, United States
- Weill Cornell Medical College, New York, New York, United States
- Montefiore Medical Center (Albert Einstein), New York, New York, United States
- Western New York Urology Associates, New York, New York, United States
- The University of North Carolina, Chapel Hill, North Carolina, United States
- Penn State Hershey State College, Hershey, Pennsylvania, United States
- Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
- Urology Associates, PC, Nashville, Tennessee, United States
- Urology San Antonio, Fredericksburg, Texas, United States
- Carmel Medical Center, Haifa, Israel
- Rabin Medical Center, Petah Tikva, Israel